Antibiotic Resistance Patterns and Genetic Diversity in Clinical Isolates of Pseudomonas aeruginosa Isolated From Patients of a Referral Hospital, Isfahan, Iran

Vaez, Hamid; Faghri, Jamshid; Esfahani, Bahram Nasr; Moghim, Sharareh; Fazeli, Hossein; Sedighi, Mansour; Safaei, Hajieh Ghasemian

doi:10.5812/jjm.20130v2

Cited by 18 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the 118 P. aeruginosa isolates investigated in this study, 51 (43.22%) were defined as MDR-PA, which was similar to the results of a study performed in China (37.90%) (Li et al, 2015). However, this number was lower than that reported by Vaez et al (2015) and Mirsalehian et al (2010) (51.80 and 87.05%, respectively). All the P. aeruginosa isolates in this study were susceptible to polymyxin E (CL), in agreement with other study (Woodford et al, 2008).…”

Section: Discussionsupporting

confidence: 88%

Prevalence of β-lactamase classes A, C, and D among clinical isolates of Pseudomonas aeruginosa from a tertiary-level hospital in Bangkok, Thailand

2016

View full text Add to dashboard Cite

Pseudomonas aeruginosa is one of the most important causes of nosocomial infection and it has increasing resistance to many antimicrobial agents. β-lactamase production is the most frequent mechanism for β-lactam resistance in P. aeruginosa. We evaluated the prevalence of β-lactamase genes in P. aeruginosa for classes A, C, and D by polymerase chain reaction, and investigated clonal diversity by pulsed-field gel electrophoresis (PFGE). We used the disk diffusion method to test 118 non-duplicate clinical isolates of P. aeruginosa for antimicrobial susceptibility. We identified 51 isolates (43.22%) as multidrug-resistant P. aeruginosa, approximately 44.91% of which were resistant to ceftazidime. β-lactamase genes were found in 80 isolates of P. aeruginosa (67.80%). The genes that encode VEB-1, AmpC, and OXA-10 were detected in 9 (7.62%), 75 (63.56%), and 18 (15.25%) of these isolates, respectively. The genes that encode PER-1, CTX-M, TEM-1 and derivatives, and SHV-1 were not found in any of the P. aeruginosa isolates. We identified 29 different pulsotypes by PFGE. Two predominant pulsotypes were found. In pulsotype 1, OXA- 10, which was co-produced with the AmpC gene, was predominant. Moreover, VEB-1-producing strains were found to be scattered in many pulsotypes, and AmpC-producing strains showed high pulsotype diversity. The prevalence of β-lactamase genes in P. aeruginosa was represented by the genetic heterogeneity of OXA-10, AmpC, and VEB-1. The predominant clone of P. aeruginosa clinical isolates was OXA-10. This raises concern about oxacillinases among P. aeruginosa clinical isolates.

show abstract

Section: Discussionsupporting

confidence: 88%

Prevalence of β-lactamase classes A, C, and D among clinical isolates of Pseudomonas aeruginosa from a tertiary-level hospital in Bangkok, Thailand

2016

View full text Add to dashboard Cite

show abstract

“…Therefore, it was possible that highly resistant Pseudomonas strains could infect burn patients in the hospitals. The results of our research were similar to some reports from Iran and other countries (9)(10)(11). Contrary to our findings, in 2013, Alikhani et al reported a higher resistance to aztreonam in 27% of P. aeruginosa isolates (12).…”

Section: Discussioncontrasting

confidence: 57%

Molecular Analysis of Pseudomonas aeruginosa Strains Isolated from Burn Patients by Repetitive Extragenic Palindromic-PCR (rep-PCR)

Sorkh

Shokoohizadeh

Rashidi

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: Infections caused by Pseudomonas aeruginosa raise an important issue in burn patients. Molecular epidemiologic studies have been used for investigating the genetic features of P. aeruginosa and rep-PCR technique has been introduced as a rapid low cost method. Objectives: This study focused on investigating the genetic similarity and antibiotic resistance pattern of P. aeruginosa isolated from the clinical samples of burn patients in a major burn center in Khuzestan Province, Iran. Methods: In a cross sectional study, a total of 75 strains of P. aeruginosa were isolated from burn patients at Taleghani hospital, which is the main burn center in Ahvaz, Iran, during May-September, 2015. Antimicrobial susceptibility of the isolates was detected using the disk diffusion method. Genetic relatedness of the isolates was analyzed by the rep-PCR technique. Results: Antimicrobial susceptibility testing showed more than 80% of P. aeruginosa isolates were resistant to ceftriaxone, cefotaxime, meropenem, piperacillin/tazobactam, ticarcillin, ciprofloxacin, and amikacin. Based on the rep-PCR analysis, 20 different common types and 20 unique patterns were illustrated among P. aeruginosa isolates. Conclusions: According to the findings of our study, there were diverse and high-level resistant P. aeruginosa strains in the major burn center in Khuzestan. Therefore, we faced troubles controlling the diverse P. aeruginosa clones in the burn patients.

show abstract

“…In the present study, 95% of the P. aeruginosa isolates were MDR, which is similar to the results of studies performed by Safaei et al (24) and Mirsalehian et al (25). However, this rate is lower than the rates reported by Katvoravutthichai (21,26,27). The prevalence of XDR strains (5%) in our study was lower than that reported by Palavutitotai et al (2018) in Thailand (22%) (28).…”

Section: Discussionsupporting

confidence: 88%

Distribution of Ambler Class A Β-lactamase Genes and Evaluation of Resistance Patterns in Multi-Drug and Extensively-Drug Resistant P. aeruginosa Clinical Isolates

2019

View full text Add to dashboard Cite

Background and Objectives: Emergence and spread of multidrug-resistant (MDR) and extensively-drug resistant (XDR) Pseudomonas aeruginosa strains could complicate antipseudomonal chemotherapy. Dissemination of resistance genes, such as βlactamases encoding genes by horizontal gene transfer can lead to development of multidrug resistance in P. aeruginosa. The purpose of this study was to investigate the latest resistance patterns in MDR and XDR strains and evaluate Ambler class A β-lactamase gene distribution in P. aeruginosa clinical isolates.Methods: One hundred molecularly and biochemically identified P. aeruginosa strains isolated from different clinical specimens were tested for sensitivity to 17 antibiotics using the Kirby-Bauer disk diffusion method. PCR was performed to detect bla TEM-1, bla SHV-1, bla REP-1 and bla VEB-1 genes. Results were analyzed using SPSS and NTSYSpc softwares.Results: Based on the results of antibiogram, the highest rate of resistance was observed against amikacin (100%), aztreonam (83%), ceftazidime (55%), cefepime (55%) and netilmicin (48%). In addition, the frequency of MDR and XDR isolates was 95% and 5%, respectively. The blaSHV-1, bla TEM-1, bla PER-1 and bla VEB-1 genes were detected in 31%, 24%, 13% and 10% of the isolates, respectively.Conclusion: Antibiotic resistance to β-lactam antibiotics and frequency of βlactamase genes were relatively high in the study area. We also found that a significant proportion of XDR strains with different antibiotic resistance profile is isolated from tracheal specimens.

show abstract

Antibiotic Resistance Patterns and Genetic Diversity in Clinical Isolates of Pseudomonas aeruginosa Isolated From Patients of a Referral Hospital, Isfahan, Iran

Cited by 18 publications

References 36 publications

Prevalence of β-lactamase classes A, C, and D among clinical isolates of Pseudomonas aeruginosa from a tertiary-level hospital in Bangkok, Thailand

Prevalence of β-lactamase classes A, C, and D among clinical isolates of Pseudomonas aeruginosa from a tertiary-level hospital in Bangkok, Thailand

Molecular Analysis of Pseudomonas aeruginosa Strains Isolated from Burn Patients by Repetitive Extragenic Palindromic-PCR (rep-PCR)

Distribution of Ambler Class A Β-lactamase Genes and Evaluation of Resistance Patterns in Multi-Drug and Extensively-Drug Resistant P. aeruginosa Clinical Isolates

Contact Info

Product

Resources

About